This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Clinical Trial Uncertainty Puts Adicet Bio’s Prula-cel Program and Financial Outlook at Risk
Adicet Bio Inc (ACET) has disclosed a new risk, in the Innovation / R&D category.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adicet Bio Inc. faces a significant risk that its clinical trials, including the ongoing Phase 1 study of prula-cel, may fail to demonstrate adequate safety or efficacy, which could block or materially delay regulatory approval and commercialization. Given the inherent uncertainty, high attrition rates, and potential for regulatory authorities to require additional costly and time-consuming studies, adverse outcomes in these trials could materially harm its business prospects and financial condition.
The average ACET stock price target is $28.25, implying 291.82% upside potential.
To learn more about Adicet Bio Inc’s risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
